Dr. Peter Berglund, Chief Scientific Officer of HDT Bio, discusses the development of a next-generation RNA vaccine platform for infectious diseases and cancer. The RNA is self-replicating, meaning that it can produce a prolonged immunological effect at a much lower dose than the current RNA vaccines. The company has a COVID-19 vaccine candidate but is also focused on emerging pandemic threats and oncology indications, both in the U.S. and internationally.
Dr. Berglund has over 25 years of experience in developing and evaluating novel vaccine technologies. A pioneer in the RNA vaccination field, Dr. Berglund has studied immune response, memory and protection against influenza and other viral infections. Previously, he was Executive Director of Research at Immune Design where he advanced products from discovery through Phase III clinical trials. Prior to that he led the vaccine division at Liquidia Technologies and vaccine discovery at AlphaVax. In those roles he has led teams of dozens and advanced more than a half-dozen products into clinical trials. Peter earned his PhD at the Karolinska Institutet and thereafter conducted post-doctoral research at the Institutet and at the Laboratory of Viral Disease at the National Institutes of Health.